07:00 , Aug 24, 2015 |  BC Week In Review  |  Clinical News

AVN-211: Phase IIb data

A double-blind, Russian Phase IIb trial in 80 schizophrenic patients in incomplete remission on stable antipsychotic therapy showed that once-daily oral AVN-211 missed the primary endpoint of improving PANSS total score from baseline to week...
07:00 , Apr 9, 2015 |  BC Innovations  |  Strategy

Back to Basics at NIMH

NIH's National Institute of Mental Health is reversing the trend of promoting translational research in publicly funded organizations with a new strategic plan that formalizes the institute's recent shift back to basic research in its...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Clinical News

AVN-211: Phase IIb started

Avineuro began a Russian Phase IIb trial to evaluate 4 and 8 mg AVN-211 once daily for 6 weeks in 80 patients with schizophrenia in a state of a partial remission on stable antipsychotic therapy....
07:00 , Apr 8, 2013 |  BioCentury  |  Product Development

AD(ing) an antagonist

Otsuka Pharmaceutical Co. Ltd. 's deal with H. Lundbeck A/S gives the Japanese pharma a piece of the most advanced serotonin (5-HT6) receptor antagonist to treat the cognitive symptoms of Alzheimer's disease. The partners expect...
07:00 , Oct 24, 2011 |  BioCentury  |  Product Development

Alzheimer's rewind

A string of Phase II and III failures in Alzheimer's disease has prompted companies to look for new targets beyond the well-known players in the core mechanism of AD - the production and accumulation of...
07:00 , Oct 28, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD); schizophrenia Serotonin (5-HT6) receptor In vitro and rat studies suggest that a class of 5-HT6 receptor antagonists could help treat cognitive impairment...
07:00 , Apr 13, 2009 |  BC Week In Review  |  Clinical News

AVN-101: Phase I started

Avineuro began an open-label, placebo-controlled, Russian Phase I trial to evaluate oral AVN-101 in 16 healthy volunteers. Avineuro Pharmaceuticals Inc. , San Diego, Calif.   Product: AVN-101   Business: Neurology   Molecular target: Serotonin (5-HT)...
07:00 , Mar 16, 2009 |  BC Week In Review  |  Clinical News

AVN-211: Phase I started

Avineuro began a placebo-controlled, dose-escalation, European Phase I trial to evaluate 2 and 4 mg/day of oral AVN-211. Avineuro Pharmaceuticals Inc. , San Diego, Calif.   Product: AVN-211   Business: Neurology   Molecular target: Serotonin...